Legato Capital Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-24,780
Closed -$401K – 597
2023
Q4
$401K Buy
+24,780
New +$405K 0.05% 456
2023
Q3
– Sell
-17,115
Closed -$275K – 608
2023
Q2
$275K Buy
+17,115
New +$282K 0.04% 488
2021
Q3
– Sell
-9,051
Closed -$409K – 282
2021
Q2
$409K Buy
+9,051
New +$401K 0.06% 271

Other funds holding NEO

Legato Capital Management's NEO Position: Q1 2024 in Review

Legato Capital Management sold out of NeoGenomics (NEO) in Q1 2024, closing a stake of 24,780 shares — an estimated $401K sold.

Legato Capital Management first reported a position in NEO in Q2 2021 and held it in 3 quarters. The position peaked at $409K in Q2 2021. 263 funds tracked by Wall St. Rank hold NEO as of Q1 2024.

  • Legato Capital Management reported no remaining NeoGenomics position as of Q1 2024 after selling out during the quarter.
  • Legato Capital Management sold 24,780 NeoGenomics shares in Q1 2024, an estimated $401K.
  • Legato Capital Management first reported a position in NeoGenomics in Q2 2021 and held it in 3 quarters.
  • Legato Capital Management's NeoGenomics position peaked at $409K in Q2 2021.
  • 263 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2024.

Based on Legato Capital Management's 13F filing for Q1 2024, filed 15 Apr 2024.